PL363576A1 - Zastosowanie (R)-ibuprofeno-metanosulfonamidu i jego soli do leczenia i zapobiegania reakcjom odrzucania przeszczepionych organów - Google Patents

Zastosowanie (R)-ibuprofeno-metanosulfonamidu i jego soli do leczenia i zapobiegania reakcjom odrzucania przeszczepionych organów

Info

Publication number
PL363576A1
PL363576A1 PL02363576A PL36357602A PL363576A1 PL 363576 A1 PL363576 A1 PL 363576A1 PL 02363576 A PL02363576 A PL 02363576A PL 36357602 A PL36357602 A PL 36357602A PL 363576 A1 PL363576 A1 PL 363576A1
Authority
PL
Poland
Prior art keywords
prevention
treatment
rejection reactions
salts
transplanted organs
Prior art date
Application number
PL02363576A
Other languages
English (en)
Other versions
PL215109B1 (pl
Inventor
Riccardo Bertini
Francesco Colotta
Roberto Novellini
Original Assignee
Dompe S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe S.P.A. filed Critical Dompe S.P.A.
Publication of PL363576A1 publication Critical patent/PL363576A1/pl
Publication of PL215109B1 publication Critical patent/PL215109B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
PL363576A 2001-02-02 2002-01-30 Zastosowanie (R)-ibuprofeno-metanosulfonamidu i jego nietoksycznych soli do wytwarzania leków PL215109B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI000206A ITMI20010206A1 (it) 2001-02-02 2001-02-02 Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
PCT/EP2002/000946 WO2002062330A2 (en) 2001-02-02 2002-01-30 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs

Publications (2)

Publication Number Publication Date
PL363576A1 true PL363576A1 (pl) 2004-11-29
PL215109B1 PL215109B1 (pl) 2013-10-31

Family

ID=11446717

Family Applications (1)

Application Number Title Priority Date Filing Date
PL363576A PL215109B1 (pl) 2001-02-02 2002-01-30 Zastosowanie (R)-ibuprofeno-metanosulfonamidu i jego nietoksycznych soli do wytwarzania leków

Country Status (26)

Country Link
US (1) US7560487B2 (pl)
EP (1) EP1355641B1 (pl)
JP (1) JP2004517948A (pl)
KR (1) KR100857898B1 (pl)
CN (1) CN1561205A (pl)
AT (1) ATE304846T1 (pl)
AU (1) AU2002250869B2 (pl)
BR (2) BRPI0206804B1 (pl)
CA (1) CA2432432C (pl)
CZ (1) CZ303665B6 (pl)
DE (1) DE60206245T2 (pl)
DK (1) DK1355641T3 (pl)
EE (1) EE05233B1 (pl)
ES (1) ES2248541T3 (pl)
HU (1) HU229070B1 (pl)
IL (1) IL157180A (pl)
IT (1) ITMI20010206A1 (pl)
MX (1) MXPA03006686A (pl)
NO (1) NO334285B1 (pl)
NZ (1) NZ526655A (pl)
PL (1) PL215109B1 (pl)
PT (1) PT1355641E (pl)
RU (1) RU2257895C2 (pl)
SK (1) SK287632B6 (pl)
WO (1) WO2002062330A2 (pl)
ZA (1) ZA200304861B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004003673T2 (de) * 2004-03-25 2007-10-04 Dompe' Pha.R.Ma S.P.A. Verwendung von N-(2-Aryl-propionyl)-sulfonamiden zur Behandlung von Rückenmarkverletzungen
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
CA2669935A1 (en) * 2006-11-13 2008-05-29 Takeda Pharmaceuticals North America, Inc. Methods for preserving renal function using xanthine oxidoreductase inhibitors
EP2308484A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
JP5978216B2 (ja) 2010-09-10 2016-08-24 タケダ ファーマシューティカルズ ユー.エス.エー. インコーポレイティド テオフィリンとフェブキソスタットの併用療法のための方法
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
HUE065802T2 (hu) * 2017-03-15 2024-06-28 Numares Ag Marker-készlet alkalmazása vesekilökõdés kockázatának meghatározására

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879283A (en) * 1985-10-03 1989-11-07 Wisconsin Alumni Research Foundation Solution for the preservation of organs
RU2008901C1 (ru) * 1991-03-29 1994-03-15 Донецкий государственный медицинский институт им.М.Горького Способ фармакологической защиты децентрализованной почки
ATE257389T1 (de) * 1992-09-17 2004-01-15 Amgen Inc Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
JPH08231413A (ja) * 1994-12-29 1996-09-10 Mochida Pharmaceut Co Ltd 臓器障害に基づく疾患の予防・治療剤
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine

Also Published As

Publication number Publication date
EE05233B1 (et) 2009-12-15
ZA200304861B (en) 2004-06-30
IL157180A (en) 2009-06-15
RU2003126600A (ru) 2005-02-27
MXPA03006686A (es) 2004-05-31
NO20033273D0 (no) 2003-07-18
ES2248541T3 (es) 2006-03-16
PT1355641E (pt) 2005-11-30
HU229070B1 (hu) 2013-07-29
SK9732003A3 (en) 2003-11-04
BRPI0206804B1 (pt) 2018-09-25
US7560487B2 (en) 2009-07-14
CA2432432A1 (en) 2002-08-15
HUP0303024A2 (hu) 2003-12-29
DE60206245T2 (de) 2006-06-14
NO20033273L (no) 2003-07-18
SK287632B6 (sk) 2011-04-05
NO334285B1 (no) 2014-01-27
WO2002062330A2 (en) 2002-08-15
EP1355641B1 (en) 2005-09-21
NZ526655A (en) 2005-02-25
RU2257895C2 (ru) 2005-08-10
EE200300340A (et) 2003-10-15
EP1355641A2 (en) 2003-10-29
WO2002062330A3 (en) 2003-04-03
CZ303665B6 (cs) 2013-02-20
DK1355641T3 (da) 2005-10-17
AU2002250869B2 (en) 2006-10-19
CN1561205A (zh) 2005-01-05
PL215109B1 (pl) 2013-10-31
CA2432432C (en) 2008-03-25
CZ20032095A3 (en) 2004-05-12
JP2004517948A (ja) 2004-06-17
KR100857898B1 (ko) 2008-09-10
BR0206804A (pt) 2004-02-03
ATE304846T1 (de) 2005-10-15
KR20030074725A (ko) 2003-09-19
US20040102520A1 (en) 2004-05-27
ITMI20010206A1 (it) 2002-08-02
HUP0303024A3 (en) 2005-07-28
DE60206245D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
ATE517624T1 (de) Behandlung von neurodegenerativen erkrankungen und krebs im gehirn
EE02971B1 (et) Droloksüfeeni või selle soolade kasutamine luuhaiguste vastase ravimi valmistamiseks
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
MXPA04004601A (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
MXPA05004247A (es) Cromonas y derivados de cromona y usos de los mismos.
EP1350511A4 (en) MEDICAL COMPOSITIONS CONTAINING ASPIRIN
EP1197210A4 (en) MEANS TO PREVENT THE CHRONIC BREATHING REACTION AS A RESULT OF AN ORGANTRANSPLANTATION
MXPA03006686A (es) Uso de metanosulfonamida de ( r ) ibuprofen y sales de la misma en el tratamiento y prevencion de las reacciones de rechazo de organos transplantados.
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
WO2003024941A1 (en) Naphthalene compounds and use thereof as drugs
ATE521344T1 (de) Calciumsalze zur behandlung von psoriasis, dermatitis und schuppen
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
JP2004517948A5 (pl)
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
PT1091746E (pt) Utilizacao de solucoes salinas isoosmoticas para a preparacao de medicamentos cerumenoliticos
IL170519A (en) Use of fenofibrate or pharmaceutically acceptable salt thereof, orlistat and pharmaceutically acceptable carrier in the manufacture of medicaments for the treatment of obesity and pharmaceutical compositions containing them
EP1325918A4 (en) INHIBITORS OF CARDIAC MUSCLE CELL APOPTOSIS AND THERAPEUTIC / PROPHYLACTIC AGENTS AGAINST HEART DISEASE
WO2003039231A3 (en) Compounds and methods for treating transplant rejection
ATE487462T1 (de) Zubereitung zur vorbeugung und behandlung von akne enthaltend zinkgluconat und kupfergluconat
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
ATE464042T1 (de) Verwendung von neboglamine zur behandlung von schizophrenie
RU2004119059A (ru) Препарат для лечения и профилактики эндометритов у коров - "альгацин"
RU99116456A (ru) Лекарственное средство для профилактики и лечения вирусных болезней животных